淋巴水肿诊断市场－全球产业规模、份额、趋势、机会及预测（按技术、疾病、最终用户、地区和竞争格局划分，2021-2031年）

全球淋巴水肿诊断市场预计将从 2025 年的 4,356 万美元成长到 2031 年的 6,835 万美元，复合年增长率为 7.80%。

此细分市场包括电阻阻抗谱和淋巴闪烁显像等医学影像技术和筛检设备，用于识别淋巴系统功能障碍并测量患者的体液储存。推动市场扩张的关键因素包括癌症倖存者次发性淋巴水肿在全球的盛行率不断上升，以及人口老化导致慢性静脉功能不全的易感性增加。这些结构性因素使得人们持续需要可靠的检测设备，以便在病情恶化前进行管理。根据淋巴教育与研究网络 (LERN) 2024 年发布的数据，淋巴水肿影响着美国约 1,000 万人和全球超过 2.5 亿人，凸显了开发精准诊断工具以支持早期治疗和改善患者预后的紧迫性。

全球淋巴水肿诊断市场扩张的主要障碍在于先进影像设备的高成本以及许多地区保险覆盖不足。缺乏专业淋巴评估的报销往往阻碍了医疗专业人员采用最新技术，并限制了患者获得重要诊断服务的机会。这种经济障碍在开发中国家的医疗资金有限，资源分配往往优先考虑急性病治疗而非慢性病管理。

市场驱动因素

癌症相关次发性淋巴水肿盛行率的上升是诊断市场的主要驱动力，尤其是在全球乳癌和骨盆腔癌存活率持续提高的情况下。医疗机构越来越重视对癌症倖存者进行早期淋巴功能障碍的倡议，因此需要频繁应用淋巴闪烁造影和电阻谱等诊断工具。由于次发性淋巴水肿是一种慢性疾病，通常在治疗后数月至数年内出现，癌症倖存者人数的不断增长导致对持续后续观察的需求持续增加。根据美国癌症协会2024年1月发布的《2024年癌症事实与数据》，预计2024年美国女性将新增约310,720例侵袭性乳癌病例。患者数量的增加直接转化为对精准检测设备需求的增长，因为这些患者面临终身慢性肿胀和併发症的风险，而这些併发症需要即时治疗。

非侵入性诊断方法的技术进步，透过实现更精准、以患者为中心的评估，进一步推动了市场成长。製造商正在将诊断设备与数位健康生态系统集成，以优化数据收集，这提高了淋巴水肿和血管疾病专科诊所的采用率。这种现代化趋势也体现在主要产业参与者的财务表现中，他们正在扩展产品系列以满足临床需求。例如，Tactile Systems Technology, Inc. 在其于 2024 年 2 月发布的「2023 财年第四季度及全年财务业绩」中报告称，其全年总收入达到 2.744 亿美元，这主要得益于对淋巴水肿管理和诊断解决方案的强劲需求。此外，全球癌症负担持续加重，需要可扩展的诊断基础设施来应对未来不断增长的病例量。 2024 年，国际癌症研究机构 (IARC) 预测癌症治疗需求将出现大规模激增，估计到 2050 年，每年将新增 3500 多万例癌症病例，这凸显了长期需要强大的淋巴水肿诊断能力。

市场挑战

高阶诊断影像系统高昂的成本以及保险覆盖不足是阻碍因素。由于报销的不确定性和投资报酬率低，医疗机构往往不愿意投资昂贵的设备，例如淋巴闪烁显像仪和电阻谱仪。在许多地区，支付方将专业的淋巴影像归类为非必要或研究性检查，导致理赔被拒，限制了其临床应用。这种资金支持的匮乏迫使医疗服务提供者依赖主观的身体检查而非精准的设备诊断，导致设备製造商的收入成长停滞不前。

此外，沉重的经济负担也成为患者接受这些诊断程序的一大障碍。根据美国整形外科医师协会统计，到2025年，保守性淋巴水肿治疗的平均费用为每位患者14,648美元，其中平均自付费用为9,765美元。如此高昂的自付费用阻碍了患者接受全面的诊断评估，并迫使医疗系统优先考虑急性治疗而非慢性病管理手段。因此，在医疗服务提供者和患者都面临不利的经济环境下，市场对先进筛检技术的需求正在下降。

市场趋势

携带式、可携式照护现场设备的出现，透过分散肢体体积测量，从根本上改变了诊断格局。临床医生正逐渐摒弃笨重昂贵的周径仪，转而越来越多地采用基于行动应用程式的3D成像解决方案，这些方案可在标准智慧型手机上提供临床等级的精确度。这种技术的普及满足了非专业、资源匮乏地区对便利筛检的迫切需求，使早期疗育无需大量资金投入。根据Docwire News（2025年3月）发表的报导「应用程式成功检测乳癌患者的淋巴水肿」的文章报道，LymphaTech 3D影像系统近期的一项检验表明，与传统週径仪方法相比，其组内相关係数（ICC）大于0.99，证实了其在广泛临床应用中的可靠性。

同时，用于远端患者监护的数位健康平台的扩展，正在为慢性病管理建立一个更整合、更协作的医疗环境。业界领先企业正转向下一代互联设备，这些设备能够无缝整合治疗方案数位资料追踪，从而提高患者依从性并长期监测疾病进展。这种策略整合正在推动强劲的商业性应用，因为医疗服务提供者优先考虑能够简化患者数据的生态系统。根据Tactile Systems Technology在2025年11月举行的“2025年第三季度财报电话会议”，其淋巴水肿治疗产品的收入达到7240万美元，同比增长11%，这主要得益于该公司互联平台Nimbl的普及和广泛应用。

目录

第一章概述

第二章调查方法

第三章执行摘要

第四章：客户评价

第五章 全球淋巴水肿诊断市场展望

• 市场规模及预测
  • 按金额
• 市占率及预测
  • 透过技术（电阻分析、电脑断层扫描、淋巴闪烁显像、磁振造影、近红外线萤光成像、超音波成像、X射线造影）
  • 依疾病分类（癌症、心血管疾病、发炎性疾病）
  • 按最终使用者（诊断中心、医院、研究和学术机构等）
  • 按地区
  • 按公司（2025 年）
• 市场地图

第六章 北美淋巴水肿诊断市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国家分析
  • 我们
  • 加拿大
  • 墨西哥

7. 欧洲淋巴水肿诊断市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国家分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

8. 亚太地区淋巴水肿诊断市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

9. 中东和非洲淋巴水肿诊断市场展望

• 市场规模及预测
• 市占率及预测
• 中东和非洲：国家分析
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 南非

第十章 南美洲淋巴水肿诊断市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国家分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章 市场动态

• 司机
• 任务

第十二章 市场趋势与发展

• 併购
• 产品发布
• 最新进展

第十三章 全球淋巴水肿诊断市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的可能性
• 供应商电力
• 顾客权力
• 替代品的威胁

第十五章 竞争格局

• ImpediMed
• BioCompression Systems
• Mego Afek
• Stryker
• Philips Healthcare
• GE HealthCare
• Siemens Healthineers
• Canon Medical
• Perimed
• Fluoptics

第十六章 策略建议

第十七章：关于研究公司及免责声明

The Global Lymphedema Diagnostics Market is projected to increase from a valuation of USD 43.56 Million in 2025 to USD 68.35 Million by 2031, expanding at a CAGR of 7.80%. This market sector encompasses medical imaging technologies and screening apparatuses, such as bioimpedance spectroscopy and lymphoscintigraphy, which are employed to identify lymphatic system dysfunction and measure fluid accumulation in patients. Key drivers fueling market expansion include the growing worldwide prevalence of secondary lymphedema among cancer survivors and an aging demographic susceptible to chronic venous insufficiency. These structural factors generate a continuous need for reliable detection instruments to manage the condition prior to its progression. As stated by the Lymphatic Education & Research Network in 2024, lymphedema affects approximately 10 million individuals in the United States and over 250 million globally, highlighting the urgent requirement for precise diagnostic tools to support early treatment and enhanced patient outcomes.

A major obstacle limiting the broader development of the Global Lymphedema Diagnostics Market is the high expense associated with sophisticated imaging machinery and the insufficiency of insurance coverage in numerous regions. The scarcity of reimbursement frameworks for specialized lymphatic assessments frequently deters medical practitioners from implementing modern technologies and restricts patient entry to critical diagnostic services. This economic hurdle is especially damaging in developing nations where healthcare funding is restricted, and resource distribution frequently favors acute medical care over systems designed for managing chronic diseases.

Market Driver

The rising prevalence of cancer-associated secondary lymphedema serves as a primary catalyst for the diagnostics market, especially as global survival rates for breast and pelvic cancers continue to improve. Healthcare providers are increasingly emphasizing surveillance initiatives to detect early-stage lymphatic dysfunction in survivors, necessitating the frequent application of diagnostic tools such as lymphoscintigraphy and bioimpedance spectroscopy. Because secondary lymphedema is a chronic condition that often manifests months or years post-treatment, the expanding population of cancer survivors generates a lasting demand for longitudinal monitoring. Data from the American Cancer Society's 'Cancer Facts & Figures 2024', released in January 2024, indicates that approximately 310,720 new invasive breast cancer cases were expected to be diagnosed in women in the United States that year. This increasing patient volume directly translates to a heightened need for accurate detection devices, as these individuals face a lifelong risk of chronic swelling and associated complications requiring immediate care.

Technological advancements in non-invasive diagnostic modalities are further driving market growth by facilitating more precise and patient-centric assessments. Manufacturers are integrating digital health ecosystems with diagnostic hardware to optimize data collection, thereby fostering higher adoption rates among clinics specialized in lymphedema and vascular disorders. This modernization is evident in the financial results of key industry players who are broadening their portfolios to address clinical needs. For instance, Tactile Systems Technology reported in their 'Fourth Quarter and Fiscal Year 2023 Financial Results' in February 2024 that the company achieved a total annual revenue of $274.4 million, fueled by strong demand for their lymphedema management and diagnostic solutions. Moreover, the global burden of cancer continues to require scalable diagnostic infrastructure to handle future caseloads; the International Agency for Research on Cancer predicted in 2024 a widespread surge in oncology needs, estimating over 35 million new cancer cases annually by 2050, which reinforces the long-term requirement for robust lymphedema diagnostic capabilities.

Market Challenge

The significant expense associated with high-end imaging systems and the absence of adequate insurance coverage act as major restraints on the expansion of the Global Lymphedema Diagnostics Market. Healthcare facilities often hesitate to invest in costly capital equipment, such as lymphoscintigraphy units or bioimpedance spectroscopy devices, due to the uncertainty of reimbursement and low return on investment. In many jurisdictions, payers classify specialized lymphatic imaging as non-essential or investigational, resulting in denied claims and restricted clinical adoption. This lack of financial support compels medical providers to rely on subjective physical examinations rather than precise instrumental diagnostics, thereby stalling the revenue growth of device manufacturers.

Moreover, the heavy financial liability placed on patients creates a significant barrier to accessing these diagnostic procedures. According to the American Association of Plastic Surgeons, in 2025, the average cost for conservative lymphedema management was $14,648 per patient, with average out-of-pocket expenses reaching $9,765. This high level of personal financial burden discourages patients from pursuing comprehensive diagnostic evaluations and compels healthcare systems to prioritize acute care spending over chronic management tools. Consequently, the market faces reduced demand for sophisticated screening technologies as the economic ecosystem remains unfavorable for both providers and patients.

Market Trends

The emergence of handheld and portable point-of-care devices is fundamentally reshaping the diagnostic landscape by decentralizing limb volume measurement. Clinicians are increasingly moving away from bulky, expensive perometers in favor of mobile application-based 3D imaging solutions that offer clinical-grade accuracy on standard smartphones. This technological democratization addresses the critical need for accessible screening in non-specialized and resource-limited settings, allowing for earlier intervention without heavy capital investment. According to Docwire News, March 2025, in the 'App Successfully Detects Lymphedema in Breast Cancer Patients' article, a recent validation of the LymphaTech 3D Imaging System demonstrated intraclass correlation coefficients of >=0.99 when compared to traditional perometer methods, confirming its reliability for widespread clinical utility.

Simultaneously, the expansion of digital health platforms for remote patient monitoring is fostering a more integrated and connected care environment for chronic management. Industry leaders are pivoting towards next-generation connected devices that seamlessly combine therapeutic delivery with digital data tracking, thereby enhancing patient compliance and enabling longitudinal surveillance of disease progression. This strategic integration is driving robust commercial adoption as healthcare providers prioritize ecosystems that streamline patient data. According to Tactile Systems Technology, November 2025, in the 'Q3 2025 Earnings Call Transcript', the company reported that lymphedema product revenue increased 11% year-over-year to $72.4 million, significantly driven by the market introduction and uptake of their connected Nimbl platform.

Key Market Players

• ImpediMed
• BioCompression Systems
• Mego Afek
• Stryker
• Philips Healthcare
• GE HealthCare
• Siemens Healthineers
• Canon Medical
• Perimed
• Fluoptics

Report Scope

In this report, the Global Lymphedema Diagnostics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Lymphedema Diagnostics Market, By Technology

• Bioimpedance Analysis
• Computed Tomography
• Lymphoscintigraphy
• Magnetic Resonance Imaging
• Near-Infrared Fluorescence Imaging
• Ultrasound Imaging
• X-Ray Lymphography

Lymphedema Diagnostics Market, By Disease

• Cancer
• Cardiovascular Disease
• Inflammatory Diseases

Lymphedema Diagnostics Market, By End User

• Diagnostic Centers
• Hospitals
• Research & Academic Institutes
• Others

Lymphedema Diagnostics Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Lymphedema Diagnostics Market.

Available Customizations:

Global Lymphedema Diagnostics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Lymphedema Diagnostics Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Technology (Bioimpedance Analysis, Computed Tomography, Lymphoscintigraphy, Magnetic Resonance Imaging, Near-Infrared Fluorescence Imaging, Ultrasound Imaging, X-Ray Lymphography)
  • 5.2.2. By Disease (Cancer, Cardiovascular Disease, Inflammatory Diseases)
  • 5.2.3. By End User (Diagnostic Centers, Hospitals, Research & Academic Institutes, Others)
  • 5.2.4. By Region
  • 5.2.5. By Company (2025)
• 5.3. Market Map

6. North America Lymphedema Diagnostics Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Technology
  • 6.2.2. By Disease
  • 6.2.3. By End User
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Lymphedema Diagnostics Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Technology
      • 6.3.1.2.2. By Disease
      • 6.3.1.2.3. By End User
  • 6.3.2. Canada Lymphedema Diagnostics Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Technology
      • 6.3.2.2.2. By Disease
      • 6.3.2.2.3. By End User
  • 6.3.3. Mexico Lymphedema Diagnostics Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Technology
      • 6.3.3.2.2. By Disease
      • 6.3.3.2.3. By End User

7. Europe Lymphedema Diagnostics Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Technology
  • 7.2.2. By Disease
  • 7.2.3. By End User
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Lymphedema Diagnostics Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Technology
      • 7.3.1.2.2. By Disease
      • 7.3.1.2.3. By End User
  • 7.3.2. France Lymphedema Diagnostics Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Technology
      • 7.3.2.2.2. By Disease
      • 7.3.2.2.3. By End User
  • 7.3.3. United Kingdom Lymphedema Diagnostics Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Technology
      • 7.3.3.2.2. By Disease
      • 7.3.3.2.3. By End User
  • 7.3.4. Italy Lymphedema Diagnostics Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Technology
      • 7.3.4.2.2. By Disease
      • 7.3.4.2.3. By End User
  • 7.3.5. Spain Lymphedema Diagnostics Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Technology
      • 7.3.5.2.2. By Disease
      • 7.3.5.2.3. By End User

8. Asia Pacific Lymphedema Diagnostics Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Technology
  • 8.2.2. By Disease
  • 8.2.3. By End User
  • 8.2.4. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Lymphedema Diagnostics Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Technology
      • 8.3.1.2.2. By Disease
      • 8.3.1.2.3. By End User
  • 8.3.2. India Lymphedema Diagnostics Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Technology
      • 8.3.2.2.2. By Disease
      • 8.3.2.2.3. By End User
  • 8.3.3. Japan Lymphedema Diagnostics Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Technology
      • 8.3.3.2.2. By Disease
      • 8.3.3.2.3. By End User
  • 8.3.4. South Korea Lymphedema Diagnostics Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Technology
      • 8.3.4.2.2. By Disease
      • 8.3.4.2.3. By End User
  • 8.3.5. Australia Lymphedema Diagnostics Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Technology
      • 8.3.5.2.2. By Disease
      • 8.3.5.2.3. By End User

9. Middle East & Africa Lymphedema Diagnostics Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Technology
  • 9.2.2. By Disease
  • 9.2.3. By End User
  • 9.2.4. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Lymphedema Diagnostics Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Technology
      • 9.3.1.2.2. By Disease
      • 9.3.1.2.3. By End User
  • 9.3.2. UAE Lymphedema Diagnostics Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Technology
      • 9.3.2.2.2. By Disease
      • 9.3.2.2.3. By End User
  • 9.3.3. South Africa Lymphedema Diagnostics Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Technology
      • 9.3.3.2.2. By Disease
      • 9.3.3.2.3. By End User

10. South America Lymphedema Diagnostics Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Technology
  • 10.2.2. By Disease
  • 10.2.3. By End User
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Lymphedema Diagnostics Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Technology
      • 10.3.1.2.2. By Disease
      • 10.3.1.2.3. By End User
  • 10.3.2. Colombia Lymphedema Diagnostics Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Technology
      • 10.3.2.2.2. By Disease
      • 10.3.2.2.3. By End User
  • 10.3.3. Argentina Lymphedema Diagnostics Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Technology
      • 10.3.3.2.2. By Disease
      • 10.3.3.2.3. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Lymphedema Diagnostics Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. ImpediMed
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. BioCompression Systems
• 15.3. Mego Afek
• 15.4. Stryker
• 15.5. Philips Healthcare
• 15.6. GE HealthCare
• 15.7. Siemens Healthineers
• 15.8. Canon Medical
• 15.9. Perimed
• 15.10. Fluoptics

16. Strategic Recommendations

17. About Us & Disclaimer